Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon therapy in multiple myeloma

J C Brouet1

  • 1Service d'Immunopathologie et d'Hématologie, Hôpital Saint Louis, Paris, France.

Nouvelle Revue Francaise D'Hematologie
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebro-meningeal localization of extramedullary haematopoiesis (EMH), a rare complication of chronic idiopathic myelofibrosis (CIM).

Neuropathology and applied neurobiology·2004
Same author

Evaluation of bone mineral density and fat-lean distribution in patients with multiple myeloma in sustained remission.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2003
Same author

Interleukin-6 stimulates HHV-8 replication in bone marrow cultures and infected cell lines.

The hematology journal : the official journal of the European Haematology Association·2002
Same author

[Chronic lymphoid leukemia].

La Revue du praticien·2002
Same author

[A macroglobulinemia with an unusual bone marrow aspect].

Annales de pathologie·2001
Same author

Study of the B cell memory compartment in common variable immunodeficiency.

European journal of immunology·2000
Same journal

XIVth Congress of the French Society of Hematology. Paris, France, February 3-4, 1995. Abstracts.

Nouvelle revue francaise d'hematologie·1995
Same journal

Improved detection of CD2 on formaldehyde-fixed non dehydrated cells.

Nouvelle revue francaise d'hematologie·1995
Same journal

Engraftment of CD34+ peripheral blood progenitor cells into multiple myeloma patients following total body irradiation.

Nouvelle revue francaise d'hematologie·1995
Same journal

Allogeneic transplantation of peripheral blood progenitor cells.

Nouvelle revue francaise d'hematologie·1995
Same journal

Selection and expansion of CD34+ cells.

Nouvelle revue francaise d'hematologie·1995
Same journal

Ex vivo hematopoietic cell expansion: a theoretical and technological challenge.

Nouvelle revue francaise d'hematologie·1995
See all related articles

Alpha-interferon shows activity in multiple myeloma treatment. While beneficial in some cases for prolonging remission, its optimal use alongside other therapies requires further study.

Area of Science:

  • Oncology
  • Hematology
  • Immunotherapy

Background:

  • Multiple myeloma is a hematologic malignancy.
  • Alpha-interferon is an immunomodulatory agent.
  • Previous studies suggest potential benefits of alpha-interferon in multiple myeloma.

Purpose of the Study:

  • To evaluate the efficacy of alpha-interferon in multiple myeloma.
  • To assess its role as a single agent or in combination therapy.
  • To determine its impact on prolonging the plateau phase in patients with partial remission.

Main Methods:

  • Review of existing clinical studies on alpha-interferon in multiple myeloma.
  • Analysis of data from trials using alpha-interferon as a single agent.
  • Evaluation of data from trials combining alpha-interferon with alkylating agents.

Related Experiment Videos

Main Results:

  • Alpha-interferon demonstrated activity in multiple myeloma.
  • Its efficacy varied across different studies.
  • Benefits were observed in prolonging the plateau phase for some patients in partial remission.

Conclusions:

  • Alpha-interferon is an active agent in multiple myeloma treatment.
  • Its effectiveness is not universal and depends on various factors.
  • Further research is needed to establish the optimal administration strategy.